Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Free Cash Flow (2016 - 2025)

IGC Pharma (IGC) has disclosed Free Cash Flow for 16 consecutive years, with -$2.1 million as the latest value for Q3 2025.

  • Quarterly Free Cash Flow fell 106.73% to -$2.1 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$5.6 million through Sep 2025, down 12.27% year-over-year, with the annual reading at -$4.9 million for FY2025, 8.06% up from the prior year.
  • Free Cash Flow for Q3 2025 was -$2.1 million at IGC Pharma, down from -$1.4 million in the prior quarter.
  • The five-year high for Free Cash Flow was -$541000.0 in Q1 2024, with the low at -$2.6 million in Q1 2021.
  • Average Free Cash Flow over 5 years is -$1.7 million, with a median of -$1.7 million recorded in 2023.
  • The sharpest move saw Free Cash Flow skyrocketed 64.45% in 2024, then plummeted 106.73% in 2025.
  • Over 5 years, Free Cash Flow stood at -$2.4 million in 2021, then grew by 8.94% to -$2.2 million in 2022, then rose by 25.78% to -$1.7 million in 2023, then grew by 18.79% to -$1.3 million in 2024, then plummeted by 57.66% to -$2.1 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$2.1 million, -$1.4 million, and -$748000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.